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2Department of Cell Biology, Vrije Universiteit Brussels, Brussels, BelgiumControlling both growth and diﬀerentiation of stem cells and their diﬀerentiated somatic progeny is a challenge in
numerous ﬁelds, from preclinical drug development to clinical therapy. Recently, new insights into the underlying molec-
ular mechanisms have unveiled key regulatory roles of epigenetic marks driving cellular pluripotency, diﬀerentiation and
self-renewal/proliferation. Indeed, the transcription of genes, governing cell-fate decisions during development and main-
tenance of a cell’s diﬀerentiated status in adult life, critically depends on the chromatin accessibility of transcription factors
to genomic regulatory and coding regions. In this review, we discuss the epigenetic control of (liver-speciﬁc) gene-transcrip-
tion and the intricate interplay between chromatin modulation, including histone (de)acetylation and DNA (de)methyla-
tion, and liver-enriched transcription factors. Special attention is paid to their role in directing hepatic diﬀerentiation of
primary hepatocytes and stem cells in vitro.
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cytes, a rapid and substantial decline of hepatic func-
tionality occurs. In particular, the xenobiotic
biotransformation capacity undergoes phenotypic
changes [1]. This progressive loss of a diﬀerentiated
hepatic phenotype in vitro plausibly results from a pro-
liferative response, elicited during hepatocyte isolation
from the liver. In fact, the cell cycle entrance triggers
the activation of several signal transduction pathways,
ultimately leading to profound alterations in gene
expression [2]. The acquisition and stabilisation of a dif-
ferentiated hepatic geno- and consequently phenotype,
i.e. liver-speciﬁc gene/protein expression, very often rely
on the concerted binding of liver-enriched transcription
factors (LETFs) and other trans-acting DNA-binding
proteins to well-deﬁned regulatory and coding regions
of target genes [3–5]. As DNA is tightly condensed into
chromatin ﬁbers by histones and other proteins, modu-
lation of chromatin compaction is a prerequisite to facil-
itate binding of transcription factors and consequential
transcriptional activation [6,7]. Epigenetic events,
including covalent histone modiﬁcations and DNA
methylation, are therefore broadly acknowledged to
play a fundamental role in the organisation of chroma-
tin architecture and hence in the strict control of gene
transcription [8,9]. For example, in proliferating hepato-
cellular carcinoma (HCC) and HCC-derived hepatoma
cell lines, inhibition of histone deacetylation and DNA
methylation is found to drastically down- and up-regu-
late genes involved in cellular proliferation and xenobi-
otic metabolism, respectively [10,11]. Consequently, it
was thought that epigenetic events may display a pre-
dominant role in the acquisition and maintenance of
the hepatocyte’s diﬀerentiated phenotype of dediﬀerenti-
ating primary hepatocytes in vitro. Alternatively, stem
cells have been proposed to produce functional hepato-
cytes as well. New insights into the molecular mecha-
nisms governing the balance between self-renewal/
proliferation and lineage-directed diﬀerentiation of
embryonic stem cells have unveiled the presence of epi-
genetic marks as being key regulatory players [9,12]. In
fact, progression from unsoiled stem cells towards their
diﬀerentiated progeny is characterized by alterations in
the epigenetic landscapes of gene regulatory and coding
regions. [9,12–15]. More speciﬁcally, locus-speciﬁc mod-
iﬁcations on histones and DNA, progressively silence
the transcription of pluripotent genes (euchro-
matic? heterochromatic state), whilst typical diﬀerenti-
ated, lineage-speciﬁc genes become activated
(heterochromatic? euchromatic state) [9,12–15]. Antic-
ipation with nuclear chromatin might thus involve a key
strategy for cell fate re-programmation.
In this review, we will discuss the key regulatory role
of epigenetic modiﬁcation in gene transcription, with
particular focus on the maintenance and the acquisition
of a diﬀerentiated geno/phenotype of primary hepato-cytes and stem cells, i.e. pluripotent embryonic stem cells
(ESCs) and multipotent mesenchymal stem/progenitor
cells (MSC), respectively.2. Epigenetic control of gene transcription
2.1. Structural chromatin modiﬁcations by histone
acetylation/deacetylation
The chromatin higher order structure can be sub-
jected to a number of reversible posttranslational modi-
ﬁcations [16]. Although the functional relevance of the
individual reactions is often unclear, it is generally
believed that the global repertoire of histone tail modiﬁ-
cations constitutes a (epigenetic) code, which aﬀects
chromatin structure and/or gene expression [17]. To
date, histone acetylation, methylation, phosphoryla-
tion/ubiquination/sumoylation, ADP-ribosylation and
glycosylation of histones were reported [6,16]. Histone
acetylation, the best-understood posttranslational his-
tone modiﬁcation, is discussed in the following
paragraphs.
2.1.1. Role of histone deacetylases in the regulation of
gene expression
Two opposing enzyme activities, i.e. histone acetyl
transferases (HATs) (recently also referred to as lysine
(K)-acetyltransfereases or brieﬂy KATs [18]) and his-
tone deacetylases (HDACs), determine the acetylation
status of the lysine residues at the N-terminal histone
tails extending out of the nucleosome [6]. Upon acetyla-
tion (Fig. 1), the positive charges on the side chains of
these lysine residues are partially neutralised, thereby
weakening the interaction with the negatively charged
phosphate groups in the DNA backbone and aﬀecting
the nucleosome stability. The degree of acetylation of
core histones can thus modulate DNA accessibility
and chromatin activity in transcription, replication,
recombination and repair [19]. Whereas actively tran-
scribed genes are characterized by highly acetylated core
histones, hypoacetylated histones are preferentially
found in transcriptionally silenced chromatin regions
[20]. Consequently, the long-standing paradigm existed
that HDAC inhibition, leading to histone hyperacetyla-
tion, was exclusively associated with transcriptional acti-
vation. Yet, evidence is accumulating of HDACs
functioning as both transcriptional activators or repres-
sors. Indeed, by removal of acetyl groups from histone
tails, HDACs do not only modulate the physical interac-
tion between histones and DNA in the nucleosomal
units, but also the message encrypted in the histones’
posttranscriptional modiﬁcations, and thus the epige-
netic/histone code [21]. Consequently, speciﬁc eﬀector
proteins, e.g. transcription factors, are recruited result-
ing in further transcriptional stimulation or silencing,
Fig. 1. HAT/HDAC-mediated transcriptional control. (A), Histone-related pathway: HATs/HDACs acetylate/deacetylate histones resulting in reduced/
augmented chromatin compaction and alternations of the histone code, respectively. (B) Non-histone related pathway: HDACs directly interfere with non-
histone protein targets, including transcription factors, nuclear hormone receptors, nuclear import factors, structural proteins and adhesion proteins.
Deacetylation of latter non-histone proteins might aﬀect diverse aspects of their protein physiology, resulting in either decreased or increased activity of
the target protein. Both pathways interconnect with each other. The transcriptional outcome thus relies on the sum of all – transcription-stimulating/
inhibiting – actions.
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HDACs have targets other than histones, including the
transcription factors p53, c-myc, NF-jB, YY-1, E2F
and GATA family [22]. HDAC-mediated deacetylation
of these non-histone proteins may aﬀect their stability,
localization, DNA-binding activity or ability to interact
with other proteins [23]. As a result, the activity of the
target protein might be augmented/reduced (Fig. 1).
In light of these data, it is clear that HDACs operate
at more than one level in the transcriptional regulation
scheme. We refer to Smith for a scrupulous review
regarding the transcriptional machinery underlying
HDACs-mediated transcriptional (in)activation [24].
2.1.2. Classiﬁcation of histone deacetylases and their role
in diﬀerentiation programs
Today, 18 HDACs have been characterized. Based on
sequence similarity, they can be classiﬁed into four dis-
tinct classes. Class I (HDAC-1,-2,-3,-8) and class II
HDACs (HDAC-4,-5,-6,-7,-9,-10) closely resemble the
yeast RPD3 and HDA1 proteins, respectively. Class
III HDACs or ‘sirtuins’ are structurally unrelated to
the other HDACs and apparently insensitive to
hydroxamate-based HDAC inhibitors (HDACi) such
as Trichostatin A (TSA) [22]. HDAC-11 is the single
representative of mammalian class IV HDACs. It dis-
plays conserved residues in the catalytic core that share
some, yet insuﬃcient, homology to both class I and II
enzymes [25–27]. Most HDACs lack intrinsic DNA-
binding activities and are therefore capable of homo-
and hetero-dimerisation. The HDAC catalytic domain
is formed by a stretch of ca. 390 amino acids consisting
of a set of conserved amino acids, which diﬀer between
class I and class II HDACs [6,28]. The active site con-
sists of a gently curved tubular pocket, a zinc-binding
site and two Asp-His charge relay systems [29].Class I HDACs (HDACs-1,-2,-3,-8) are generally
small nuclear enzymes [27] that participate in cell cycle
progression [25] and the regulation of housekeeping
genes [28]. Class II HDACs (HDACs-4,-5,-6,-7,-9,-10)
share some domain similarity with yeast HDA1
[25,27]. They can be subdivided into class IIa HDACs
(HDACs-4,-5,-7,-9) and class IIb HDACs (HDAC-6
and -10) [30]. With the exception of HDAC-10, class
II HDACs show a restricted tissue-speciﬁc expression
pattern with the highest expression found in heart,
brain and skeletal muscle [28]. They are larger than
class I HDACs and shuttle between cytoplasm and
nucleus. In the nucleus, they mediate cellular prolifera-
tion and transcriptional repression of diﬀerentiation-
related genes, leading to loss of the diﬀerentiated phe-
notype [25]. This was particularly shown for class IIa
HDACs-4,-5,-7,-9 isoforms in muscle cell diﬀerentia-
tion [31]. Class IIa HDACs, and principally HDAC-
4, are also implemented in stress signaling processes,
such as cardiac/chondrocyte hypertrophy and neuronal
cell death. [32–34]. Most of these functions are medi-
ated by interactions with the MEF2 transcription fac-
tor family [32]. In contrast to other HDACs, Class
IIb HDAC-6 can accomplish cytoplasm-located func-
tions as well. More speciﬁcally, HDAC-6 functions at
the crossroads between two cellular signaling systems,
i.e. protein lysine acetylation and ubiquitination [35].
This unique feature expounds its protective role against
the accumulation of cytotoxic misfolded protein aggre-
gates within cells [35]. In addition, HDAC-6 and class I
HDAC-3 regulate osteoblast diﬀerentiation and bone
formation via interaction with transcriptional regula-
tors such as Runx2 [35,36]. Likewise, class I HDAC-
1, in complex with myoD, mediates repression of
muscle-speciﬁc gene expression in undiﬀerentiated myo-
blasts [37]. In general, class I HDACs overexpression
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comitant shift towards dediﬀerentiation, while levels
drop during diﬀerentiation processes. For example, in
normal small intestine, the HDAC-3 expression is max-
imal in proliferating cells at the crypt base and is mark-
edly decreased at the villus tip, harbouring more
diﬀerentiated cells [38]. In comparison, 90% of cells
residing in adenomas of small intestine are HDAC-
3+. Basically, overexpression of distinct HDACs
appears in various tumor specimens, e.g. HDAC-1 in
prostate, gastric and colon tumors, HDAC-2 in colo-
rectal, cervical and gastric cancer [26], and HDAC-3
in colon cancer [38]. Speciﬁc inhibition of HDAC-3
by RNA interference could inhibit proliferation of
colon cancer cell lines and increase both expression
and activity of the diﬀerentiation marker alkaline phos-
phatase [38]. As for liver-speciﬁc functions of HDACs,
recently a crucial role was credited to HDAC-3 in liver
homeostasis and development. In this respect, HDAC-
3 absence in zebraﬁsh leads to abnormalities in liver
development, [39] whilst conditioned deletion of
HDAC-3 in mice induces severe disruption of carbohy-
drate and lipid metabolism, resulting in organ hyper-
trophy and hepatocellular damage [40]. HDAC-1
overexpression in transgenic mice, on the other hand,
results in a high incidence of hepatic steatosis and
nuclear pleomorphism concomitant with altered
expression of genes involved in cell cycle, apoptosis,
and lipid metabolism such as p53, PPARc, Bak and
p21 [41,42]. Also, a number of studies provide evidence
for the involvement of HDACs and HATs in the tran-
scriptional regulation of liver-speciﬁc genes by LETFs.
This issue will be thoroughly discussed in a later
section.
Brieﬂy, these data indicate that modulating the
expression of speciﬁc HDACs might involve a strategy
to (re)activate diﬀerentiation programs.
2.1.3. HDAC inhibitors: types and eﬀects
Currently, several structurally diverse compounds
both natural and synthetic, are known as HDACi. These
include short-chain fatty acids, (non)-cyclic hydroxa-
mates, (non)-epoxyketone-containing cyclic tetrapep-
tides, benzamides and miscellaneous structures [43].
Hydroxamate-based inhibitors of classes I and II are
promising since they were repeatedly shown to selec-
tively inhibit tumor growth in animals at low (micromo-
lar) and apparently non-toxic doses [32]. Basically, in
recent years, HDACi have emerged as promising thera-
peutics for the treatment of several malignancies, includ-
ing leukaemia, solid tumors and non-solid cancers such
as multiple myeloma [27]. In that respect, Vorinostat
has recently been approved by the FDA for the treat-
ment of advanced primary cutaneous T-cell lymphoma,
whilst several other hydroxamate-containing HDACi
are being tested in phases I and II clinical trials for theirtherapeutic potential [44,45]. Having seen the growth-
inhibiting and diﬀerentiation-promoting features of
hydroxamate-based HDACi in tumor cells, including
hepatoma cells [10,11,46–48], our group successfully
applied these compounds to stabilize the diﬀerentiated
phenotype of normal primary hepatocytes in vitro
[1,2,49–52]. This will be discussed later in this review.
2.2. DNA methylation
2.2.1. Role of DNA methyltransferases in the regulation
of gene expression
Reversible DNA methylation occurs at the cytosine–
guanine dinucleotides (CpGs) in the DNA and includes
addition of a methyl group to the carbon-5 position of
cytosine [53]. DNA methylation patterns are estab-
lished by DNA methyltransferases (DNMTs), catalyz-
ing the addition of a methyl group derived from the
methyl donor S-adenosyl methionine [17,54]. The cata-
lytic activity of these enzymes is accomplished by a
highly conserved C-terminal domain, present in all
DNMTs.
In the mammalian genome, CpGs are not uniformly
distributed. CpG islands, comprising >1 CpG per 80
base pairs [55], are particulary present in/near gene pro-
motor regions. They are usually unmethylated, thereby
allowing gene expression [53–55]. The distribution of
(un)methylated CpGs diﬀers, however, within distinct
cell types due to the interplay between DNA methyla-
tion/demethylation, giving a cell-type speciﬁc DNA
methylation pattern [17]. Passive DNA demethylation
occurs during DNA replication by chemically blocking
DNMTs [17]. The exact mechanism of active DNA rep-
lication-independent demethylation still remains elusive.
Recent data suggest the involvement of identical
enzymes in both the establishment of DNA methylation
and demethylation patterns [56]. For example, the meth-
ylated DNA-binding protein MBD2 also displays
demethylase activity [57]. Additional information is
needed to unravel this tangled web.
2.2.2. Classiﬁcation of DNA methyltransferases and their
role in diﬀerentiation programs
Based on structural diﬀerences in their regulatory N-
terminal domain, three distinct families of DNMTs, i.e.
DNMT1, DNMT2 and DNMT3, have currently been
identiﬁed. All are expressed in human liver tissue [58].
DNMT1 is the most abundant DNMT in mammals
and mainly methylates hemimethylated GpGs. This
‘maintenance’ DNMT is particulary involved in main-
taining DNA methylation patterns during DNA replica-
tion [54,58,59]. It also shows activity towards
unmethylated DNA and plays a role in de novo DNA
methylation [60]. DNMT2 is the least distinguished
DNMT and lacks the regulatory N-terminal domain
present in other DNMT enzyme families [59]. Its associ-
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yltransferase activity suggest a possible role in epigenetic
regulation [61,62]. The DNMT3 family contains three
diﬀerent DNMTs, i.e. DNMT3a, DNMT3b and
DNMT3L. DNMT3a and DNMT3b, characterized as
de novo DNMTs, mainly methylate unmethylated CpGs
and establish new DNA methylation patterns during
early embryonal development [54]. They plausibly coop-
erate with DNMT1 to maintain the DNA methylation
pattern [63]. DNMT3L is a methyltransferase-like pro-
tein without intrinsic DNMT activity [59,64]. It interacts
with DNMT3a/DNMT3b and directly modulates their
catalytic activity [65].
DNMTs play a crucial role in the onset of chromatin
remodelling and gene expression regulation. They are
responsible for maintaining telomere integrity [66] and
methylation pattern acquisition during gametogenesis,
embryogenesis and somatic tissue development [67].
Several studies performed in tumor cell lines, including
HepG2 cells [68,69], also indicate the occurrence of cell
cycle arrest, apoptosis and cellular diﬀerentiation upon
DNMT inhibition. Accordingly, it has been suggested
that modulation of the expression of speciﬁc DNMTs
might involve a strategy to target the diﬀerentiation sta-
tus in developing and proliferating and consequently
dediﬀerentiating cells.
2.2.3. DNMT inhibitors: types and eﬀects
Today, a number of synthetic and natural DNMT
inhibitors (DNMTi) exist. (i) The group of nucleoside
analogue DNMTi contains several structural analogues
of deoxycytidine, including 5-azacytidine (azacytidine,
5-AzaC), 5-Aza-20-deoxycytidine (decitabine, 5-Aza-
dC), arabinosyl-5-azacytidine (fazarabine), 5-6-dihy-
dro-5-azacytidine (DHAC) and 2-pyrimidone-1-b-D-
riboside (zebularine) [70] (Fig. 2). These analogues,
with the exception of zebularine, are modiﬁed at the
carbon-5 position of the pyrimidine base cytosine
[71]. After phosphorylation and incorporation in
DNA/RNA, they form covalent bounds with DNA
methyltransferases, resulting in passive demethylation
upon replication [72]. The use of nucleoside analogue
DNMTi in tumor cells results, like HDACi, in cellFig. 2. Nucleoside anacycle arrest, induction of apoptosis and diﬀerentiation
[10,69]. In addition, latter DNMTi were applied by
our group to maintain diﬀerentiation in normal pri-
mary hepatocytes [73]. This issue will be discussed in
the next section.
(ii) The non-nucleoside analogue DNMTi represent a
heterogeneous group of DNMTi enclosing molecules
such as derivatives of 4-aminobenzoic acid (procaine
and procainamide), the main compound in green tea,
(-)-epigallocatechin-3-gallate (EGCG) [74,75] and psam-
maplins from the sponge Pseudoceratina purpurea [76].
Procain and procainamide directly bind to CpG-rich
DNA, interrupting the interaction between DNMTs
and their target DNA sequences. EGCG and psammap-
lins are both involved in several cellular processes and
also aﬀect enzymes other than DNMT [75]. Until now,
the DNMTs inhibition mechanisms of EGCG and
psammaplins remain unclear.
2.3. Interplay between DNA methylation and histone
acetylation
A tight correlation exists between [gene expression
and DNA methylation] and [chromatin structure and
DNA methylation]. Suppression of gene expression is
frequently associated with methylated DNA and a dense
chromatin structure, whereas active transcription is
associated with unmethylated DNA and hyperacetylat-
ed open chromatin [17] (Fig. 3). Initially, DNA methyl-
ation was thought to unidirectionally aﬀect chromatin
structure. However, recent data in cancer cells now sug-
gest a mutual interplay between both epigenetic modiﬁ-
cations [17]. For example, in several cancer cell lines,
combinations of DNMTi and HDACi have synergistic
eﬀects on the cellular homeostasis [69,77,78]. Accord-
ingly, so far, several ‘cocktails’ are in clinical trials as
chemotherapeutics [79]. Also, in vitro, our group discov-
ered a synergistic eﬀect of DNMTi and HDACi with
respect to the diﬀerentiated phenotype of normal pri-
mary cells [73]. This will be further explained in the next
section.
In summary, our ﬁndings show that transcription of
genes, governing maintenance of a cell’s diﬀerentiatedlogue DNMTi.
Fig. 3. Epigenetic control of gene transcription. Inhibition of gene transcription typically corresponds to hypermethylated CpG islands in gene promoter
regions and deacetylated histone tails at local chromatin domains. The indirect mechanism of gene silencing may involve binding of methyl-binding
proteins (MeCp) to methylated cytosine and subsequent recruitment of HDAC-corepressor (CoR) complexes, resulting in a non-permissive
heterochromatin status that blocks binding of transcription factors (TF) and polymerase II RNA complexes (PolII) to target promoter sequences. The
direct mechanism may involve the direct interference of TF with HDAC or methylated CpG sites within the promoter. HDAC inhibitors (HDACi) and
DNMT inhibitors (DNMTi) modulate the chromatin structure. They create an open, transcriptionally active euchromatin conﬁguration at gene coding
and regulatory regions, accessible for TF, thereby facilitating gene transcription. Abbreviations: 5-AzaC, decitabine; M, 5-methyl cytosine at CpGs; SB,
sodium butyrate; TSA, trichostatin A; VPA, valproic acid.
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plished via targeting the expression of DNMTs and/or
HDACs with increased chromatin accessibility of tran-
scription factors to their target DNA as a result.3. Epigenetic modiﬁers as potent diﬀerentiation-
promoting compounds in vitro
3.1. Acquisition and stabilisation of a diﬀerentiated
hepatic phenotype in vitro: an interplay between
chromatin remodelling and liver-enriched transcription
factors
Of major interest, at least from a pharmaco-toxico-
logical point of view, is the ability of hepatocytes to pro-
tect the organism from toxic chemical insults.
Hepatocytes dispose of an ingenious multi-step enzy-
matic clearance system, i.e. xenobiotic biotransforma-
tion, and therefore constitute the main cell type of
interest for in vitro hepatotoxicity and drug metabolism
studies to date [80].
Ex vivo, though, cell–cell and cell–extracellular
matrix disruptions, resulting from collagenase perfusion
and subsequent oxidative stress response, trigger the
activation of several ‘proliferative’ signaling cascades
[81]. Unlike hepatocytes in vivo, primary hepatocytes
in culture are unable to completely rediﬀerentiate upon
proliferation, resulting in a loss of the diﬀerentiated phe-
notype and concomitant deterioration of cytochrome
P450 (CYP)-mediated xenobiotic biotransformation
capacity [2,81]. Another essential factor is the substan-
tial decline in LETFs, controlling the transcription ofnumerous liver-speciﬁc genes [3–5,53,81–84]. Indeed,
hepatocyte proliferation and diﬀerentiation are predom-
inantly regulated at the transcriptional level [85]. Basi-
cally, eukaryotic gene transcription relies on the
combinatorial binding of multiple speciﬁc trans-acting
DNA-binding proteins, i.e. transcription factors, to par-
ticular DNA-sequence motifs in regulatory elements of a
speciﬁc gene. Eﬃcient gene expression is further often
determined by interplays between diﬀerent transcription
factors, either adjacently or distantly located on the pro-
moter, and by protein–protein interactions between
transcription factors and coactivators/corepressors
[7,13,82]. Additionally, eﬃcient binding of transcription
factors and associated proteins to their cognate DNA-
sequences requires a permissive chromatin conﬁguration
in order to drive gene expression The dynamic modula-
tion of the chromatin architecture by e.g. DNA methyl-
ation and/or covalent histone modiﬁcations represents
thus a basic machinery for transcriptional activation,
repression and derepression [7–9,13–15] (Fig. 3).
In hepatocytes, the liver-enriched transcription fac-
tors play an elemental role in hepatocyte-speciﬁc gene
expression [3–5,82,85], and are as such key regulators
of liver development, architecture and physiology. These
trans-acting DNA-binding proteins are predominantly,
but not exclusively, expressed in liver. It is hypothesized
that the coordinated and timely expression of LETFs, in
concert with ubiquitously expressed transcription fac-
tors such as NF1, Oct-1, Hex and other LETFs, is pre-
requisite for hepatocyte diﬀerentiation and constitutive
liver-speciﬁc gene expression, including CYP-mediated
xenobiotic biotransformation [4,82,84,85]. Evidence is
accumulating that recruitment of coactivators/corepres-
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through post-translational histone modiﬁcations,
mainly determine their transactivation potential. In this
context, the transcriptional activation of LETFs criti-
cally depends on the recruitment of co-activator proteins
with intrinsic HAT activity, such as CREB-binding pro-
tein (CBP), p300/CBP-associated factor (P/CAF) and
SRC1, whereas co-repressor complexes containing
HDAC negatively regulate liver-speciﬁc gene expression
[86–107]. In detail, HNF-4a, directly interacts with
SRC1, CBP and p300, resulting in its increased tran-
scriptional activity [86–92]. The level of upregulation is
isoform-dependent [92,93]. In human hepatoma cells,
transactivation of CYP1A1, CYP1A2 and CYP2C9 by
HNF-4a relies on the presence of the PPAR-gamma
coactivator 1alpha (PGC-1a) [94]. PGC-1a, a key regu-
lator of hepatic gluconeogenesis, lacks HAT-activity,
but enables transcription through the assembly of a
complex, containing SRC1 and CBP/p300 [95]. Like-
wise, in diﬀerentiating Caco2-cells, Rb strengthens
HNF-4-dependent activation of the a-antitrypsin gene
through reinforcement of the SRC-coactivator function
[96]. Conversely, interaction with SMRT or p53, recruit-
ing HDACs to transcription factors, represses HNF-4a
activity [92,97,98]. HNF-1a, on the other hand, physi-
cally interacts with the HATs CBP/p300, P/CAF,
SRC-1, and RAC3 [99,100]. CBP and PCAF, on one
hand, and CBP and p300, on the other hand, synergisti-
cally upregulate HNF-1-mediated transactivation
[100,101], whilst association of HNF-1a with HDAC1 –
through NCoR– impairs its transcriptional activity.
Treatment with the HDACi TSA disrupts latter core-
pressor complex, enhancing in turn HNF-1a-mediated
transcription [102]. A good example of LETFs acting
in a cooperative, synergistic regulatory network is the
interaction between HNF-6 and HNF-3. In this respect,
HNF-6 potentiates HNF-3b transcriptional activity by
recruiting p300/CBP HAT proteins, [103] whilst HNF-
6-dependent transcription is stimulated by complex for-
mation between HNF-6 and C/EBPa, also recruiting
coactivator CBP [104]. The transactivation potential of
C/EBPa, in turn, is promoted by direct interaction with
either CBP/p300 or Rb [105–107]. Apparently, this
binding to C/EBPa robustly stimulates nucleosomal
HAT activity of CBP [108]. C/EBPb-dependent transac-
tivation is further mediated by direct acetylation
through association with the HATs p300 and PCAF
[109–112]. Conversely, interaction between SMRT or
subcomponents of the Sin3 complex, e.g. Sin3a, and
HDAC1 represses its transcriptional activity [112]. Of
particular interest is HNF3 as, in contrast to other LET-
Fs, it directly aﬀects chromatin conformations of
numerous hepatic genes such as albumin (ALB) and a-
foetoprotein (AFP), likely without interference with
intermediary coactivators bearing HAT-activity or
ATP-dependent enzymes. More speciﬁcally, the C-ter-minal domain of the protein binds to histones H3/H4
within highly compacted chromatin, creating a local,
open nucleosomal domain, which facilitates further
interactions between transcription factors, such as
GATA4 and other LETFs, and DNA [113–115]. This
HNF3-mediated transcriptional competence is desig-
nated as a prerequisite for the onset of liver ontogeny,
and more speciﬁcally for the developmental activation
of genes required for hepatocyte diﬀerentiation and
function.
3.2. Eﬀect of HDAC and DNMT inhibition on liver-
speciﬁc gene expression
An overview of the most important hepatic genes
aﬀected by HDACi and DNMTi in various in vitromod-
els is presented in Table 1. Out of these data, it appears
that both the cellular origin and the type, concentration
and exposure time of epigenetic modiﬁer used, critically
determine the ﬁnal outcome. In transformed cells,
including colon cells [116–118], glioma cells [119,120],
pancreatic cells [121], breast cells [122] and hepatoma
cells [11], HDACi-mediated growth arrest is frequently,
at least in vitro, associated with induction of diﬀerentia-
tion. As such, HDAC inhibition upregulates C/EBPa,
HNF-1a, HNF-3a, HNF-3b and HNF-4a levels in vari-
ous hepatoma cells, resulting in increased CYP expres-
sion [11]. Yet, in spite of this beneﬁcial outcome, the
contribution of HDACi in long-term in vitro models is
hampered by co-occurrence of cell death. Indeed,
HDACi, including TSA, butyrate, valproic acid, SAHA,
OSU-HDAC42 and ITF2357, induce both in vitro and
in vivo apoptosis in hepatoma cells [11,46–48]. For exam-
ple, SAHA reduces, dose- and time-dependently, the via-
bility of HepG2 and Huh6 hepatoma cells as a result of
concomitant activation of both extrinsic and intrinsic
apoptosis signaling cascades [123]. In contrast, primary
hepatocytes are relatively well-resistant against HDAC-
i-induced apoptosis [2,49,50,124,125]. In this context,
exposure of normal primary rat hepatocytes to TSA
and 5-(4-dimethylaminobenzoyl)-aminovaleric acid
hydroxamide (4-Me2N-BAVAH) upregulates C/EBPa
and HNF-4a expression [49], which in turn increases
CYP protein and activity levels (Figs. 4 and 5), gap junc-
tional communication and ALB secretion, without any
evidence of cell death [2,49,51,52,126,127]. Moreover,
in epidermal growth factor (EGF)-stimulated primary
rat hepatocytes, we could demonstrate that TSA and 4-
Me2N-BAVAH even delay the onset of spontaneous
apoptosis as evidenced by reduced pro-caspase-3 pro-
cessing, decreased pro-apoptotic Bid and Bax levels
and increased anti-apoptotic BclxL expression [2,50].
Further indication for the involvement of histone
acetylation in the transcriptional activation of hepatic
genes is supported by enhanced activity of several LET-
Fs, including HNF-3c, HNF-4a and C/EBPa, on the
Table 1
Eﬀects of epigenetic modiﬁers on the expression of important liver genes in various in vitro models.
Epigenetic modiﬁer Species Model Regulationa Reference
HDAC inhibition
Phase I biotransformation
CYP1A1 TSA Rat Primary hepatocytes " [49]
Human Mammary carcinoma MCF-7 cells " [186]
Human HeLa cells " [186]
SAHA Human Mammary carcinoma MCF-7 cells " [187]
CYP1A2 TSA Human Mammary carcinoma MCF-7 cells " [186]
Human HeLa cells " [186]
Mouse Primary hepatocytes " [188]
Butyrate Mouse Primary hepatocytes " [188]
CYP1B1 TSA Human Mammary carcinoma MCF-7 cells " [186]
Human HeLa cells " [186]
Human HepG2 hepatoma cells  [191]
CYP2B1/2 TSA Rat Primary hepatocytes " [49]
Valproate Rat Primary hepatocytes " [190]
CYP3A4 TSA Human HepG2 hepatoma cells  [129]
Human HepG2 hepatoma cells " [131]
CYP3A2 TSA Rat Primary hepatocytes " [49]
ADH1A TSA Human HepG2 hepatoma cells  [191]
HeLa cells 
ADH1B TSA Human HepG2 hepatoma cells  [191]
HeLa cells 
ADH1C TSA Human HepG2 hepatoma cells " [191]
HeLa cells 
FMO3 TSA Human HepG2 hepatoma cells  [192]
Phase II biotransformation
GSTP1 TSA Human Hep3B hepatoma cells  [193]
Butyrate Human Colon carcinoma HT29 cells " [194]
Butyrate Human Primary colon cells  [195]
GSTA1/2 Butyrate Human Colon carcinoma HT29 cells " [194]
Human Primary colon cells " [195]
GSTA4 TSA, MS-275, VPA Mouse MC3T3-E1 preosteoblasts " [196]
GSTM2 Butyrate Human Colon carcinoma HT29 cells " [194]
GSTT1/2 Butyrate Human Colon carcinoma HT29 cells  [194]
Human Primary colon cells " [195]
UGT2B7 VPA Human Prostate carcinoma LNCaP cells " [197]
UGT2B11 VPA Human Prostate carcinoma LNCaP cells " [197]
SULT2B1 TSA Human HaCaT keratinocytes " [198]
Ammonia removal TSA Human HepG2 and Huh-7 hepatoma cells " [11]
Albumin synthesis/secretion TSA Human HepG2 and Huh-7 hepatoma cells " [11]
Rat Primary hepatocytes " [2,49]
Gap junctional intercellular communication
Cx32 TSA Human Huh-7 hepatoma cells  [199]
Human Neural progenitor cells " [200]
Human kB nasopharyngeal tumor cells  [201]
Human Prostate carcinoma cells " [202]
Human Normal prostate epithelial cells " [202]
Rat Primary hepatocytes " [52]
4-Me2N-BAVAH Rat Primary hepatocytes " [51]
Cx26 TSA Human Huh-7 hepatoma cells  [199]
Rat Primary hepatocytes ; [52]
4-Me2N-BAVAH Rat Primary hepatocytes ; [51]
Cx43 TSA Human Huh-7 hepatoma cells ; [199]
Rat Primary hepatocytes " [52]
SAHA Rat Ras transformed WB-F344 liver epithelial cells " [203]
Human Peritoneal mesothelial cells " [203]
Rat C6 glioma cells " [204]
Phenylbutyrate Human Glioblastoma cells " [120]
Human Glioblastoma cells " [205]
Human Neural progenitor cells " [200]
Human kB nasopharyngeal tumor cells " [201]
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Table 1 (continued)
Epigenetic modiﬁer Species Model Regulationa Reference
Rat Glioma cells  [205]
Sodium butyrate Human kB nasopharyngeal tumor cells " [201]
Human Glioblastoma cells  [205]
4-Me2N-BAVAH Rat Primary hepatocytes ; [51]
Liver-enriched transcription factors
C/EBPa TSA Human HepG2 hepatoma cells " [10]
Rat Primary hepatocytes " [49]
SAHA Human Pancreatic carcinoma PANC-1 cells " [121]
C/EBPb Butyrate, TSA Rat Intestinal epithelial cell line IEC-6  [206]
C/EBPd Butyrate, TSA Rat Intestinal epithelial cell line IEC-6  [206]
HNF1a TSA Rat Primary hepatocytes  [49]
HNF1b Depsipeptide Human Papillary thyroid cancer cells ; [207]
HNF4a TSA Rat Primary hepatocytes " [49]
Other
Apolipoprotein CIII TSA Human HepG2 and Huh-7 hepatoma cells " [11]
HCFX TSA Human HepG2 and Huh-7 hepatoma cells " [11]
Glutamine synthetase TSA Human HepG2 and Huh-7 hepatoma cells " [11]
DNMT inhibition
Phase I biotransformation
CYP1A1 5-Aza-dC Human Mammary carcinoma MCF-7 cells " [186]
Human HeLa cells " [186]
CYP1A2 5-Aza-dC Human Mammary carcinoma MCF-7 cells " [186]
Human HeLa cells " [186]
Mouse Primary hepatocytes  [208]
Mouse Hepa1c1c7 hepatoma cells  [208]
CYP1B1 5-Aza-dC Human Mammary carcinoma MCF-7 cells " [186]
Human HeLa cells " [186]
5-AzaC Human HepG2 hepatoma cells  [189]
CYP3A4 5-Aza-dC Human HepG2 hepatoma cells " [10]
CYP3A5 5-Aza-dC Human HepG2 hepatoma cells " [10]
CYP3A7 5-Aza-dC Human HepG2 hepatoma cells " [10]
FMO3 5-Aza-dC Human HepG2 hepatoma cells " [192]
Phase II biotransformation
GSTP1 5-Aza-dC Human Hep3B hepatoma cells " [193]
Procainamide Human LNCaP prostate cancer cells " [74]
UGT1A6 5-Aza-dC Human HepG2 hepatoma cells " [10]
UGT2B15 5-Aza-dC Human HepG2 hepatoma cells " [10]
UGT2B28 5-Aza-dC Human HepG2 hepatoma cells ; [10]
Gap junctional intercellular communication
Cx32 5-Aza-dC Human Caki-2 renal cell carcinoma cells " [209]
Human Caki-2 renal cell carcinoma cells " [210]
Human HK-2 renal tubular cells  [209]
Cx26 5-Aza-dC Human Mammary carcinoma cells " [211]
Human Mammary carcinoma cells  [212]
Human Lung cancer cells " [213]
Human Esophageal cells  [214]
Cx43 5-Aza-dC Human Esophageal cancer cells  [214]
Human Cervical adenocarcinoma cells " [215]
Human CNE-1 nasopharyngeal cancer cells " [216]
Liver-enriched transcription factors
C/EBPa 5-Aza-dC Human HepG2 hepatoma cells  [10]
C/EBPb 5-Aza-dC Human HepG2 hepatoma cells ; [10]
C/EBPc 5-Aza-dC Human HepG2 hepatoma cells ; [10]
Other
GLUT2 5-Aza-dC Mouse Primary hepatocytes " [217]
Mouse Hepa1c1c7 hepatoma cells " [217]
ADH1A 5-Aza-dC Human HepG2 hepatoma cells  [191]
HeLa cells 
(continued on next page)
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Table 1 (continued)
Epigenetic modiﬁer Species Model Regulationa Reference
ADH1B 5-Aza-dC Human HepG2 hepatoma cells " [191]
HeLa cells 
ADH1C 5-Aza-dC Human HepG2 hepatoma cells " [191]
HeLa cells 
HDAC + DNMT inhibition
Liver-enriched transcription factors
C/EBPa TSA + 5-Aza-dC Human HepG2 hepatoma cells " [10]
Phase I biotransformation
ADH1A TSA + 5-Aza-dC Human HepG2 hepatoma cells  [191]
HeLa cells 
ADH1B TSA + 5-Aza-dC Human HepG2 hepatoma cells " [191]
HeLa cells 
ADH1C TSA + 5-Aza-dC Human HepG2 hepatoma cells " [191]
HeLa cells 
a, unchanged; ", upregulation; ;, downregulation.
Abbreviations: ADH, alcohol dehydrogenase; 5-AzaC, 5-Azacytidine; 5-Aza-dC, 5-Aza-20deoxycytidine, decitabine; C/EBP, CCAAT/enhancer
binding protein; Cx, connexin; CYP, cytochrome P450; FMO, ﬂavine monooxygenase; GLUT, glucose transporter; GST, glutathione S-transferase;
HNF, hepatocyte nuclear factor; 4-Me2N-BAVAH, 5-(4-dimethylamniobenzoyl)-aminovaleric acid hydroxamate; SAHA, suberoylanilide
hydroxamic acid; SULT, sulfotransferase; TSA, Trichostatin A; UGT, uridine guanyl transferase.
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CYP3A7, CYP7A1 and glucose-6-phosphatase upon
exposure to TSA or short chain fatty acids, such as
butyrate [57,128,129]. In addition, HDAC inhibition is
implemented in the aryl hydrocarbon receptor (AhR)-
mediated induction of CYP1A1 and CYP1A2 [130],
and CYP3A4 induction by rifampicin [131]. Next to
genes coding for xenobiotic biotransformation enzymes,
HDACi also stimulate the transcription of other liver-
speciﬁc genes, including phosphoenol-pyruvate carboxy-
kinase [57], HCFX [11], apolipoprotein CIII [11],
glucose-6-phosphatase [57] and glutamine synthetase
[11]. They also promote ALB synthesis and secretionFig. 4. Eﬀects of TSA on phase I CYP-dependent biotransformation activity.
exposed to 0.083% (v/v) ethanol as solvent control [SC] or 25 lM TSA [T] for 7
CYP3A2 protein expression were analysed by means of immunoblotting. In ord
were determined, as latter LETF, in contrast to C/EBPa and HNF-4, is not aﬀe
independent experiments are shown. (B) After 2, 4 and 7 days of culture PRO
percentage of the values found for freshly isolated primary rat hepatocytes, i.e.rate, ammonia removal and gap junctional intercellular
communication [2,11,50–52] (Table 1).
DNA methylation marks, on the other hand, are cru-
cial for developmental and tissue-speciﬁc transcription
of numerous liver-speciﬁc genes, including ALB [132],
AFP [133], Cx43 [134], Cx32 [134], human CYP2E1
[135], human CYP1A2 [136], rat CYP2D3 and CYP2D5
[137], mouse CYP2D9 [138], mouse CYP2A4 [139], and
human SULT1A1 [140]. In addition, in HepG2 cells,
CYP3A4, CYP3A5 and CYP3A7 levels were raised
upon DNMT inhibition by 5-Aza-dC, whilst C/EBPb
and C/EBPc were decreased. Combined exposure to
TSA and 5-Aza-dC, but not to 5-Aza-dC alone upregu-Hepatocytes were cultured and remained either unexposed [C] or were
days. (A) After 2 [D2], 4 [D4] and 7 days [D7], CYP1A1, CYP2B1 and
er to control for equal loading of proteins, expression levels of HNF-1a
cted by culture time or exposure to TSA. Representative images for three
D (CYP2B1)-dependent activities were measured. Data are expressed as
7.7 ± 3.1 pmol/min/mg microsomal protein. Values represent mean ± SD.
Fig. 5. Eﬀects of 4-Me2 N-BAVAH on phase I CYP-dependent biotransformation activity. Cultured hepatocytes were either exposed to 0.05% (v/v)
ethanol as a solvent control [C] or to 50 lM 4-Me2N-BAVAH [B] for 7 days. (A) After 4 [D4] and 7 days [D7], CYP1A1, CYP2B1 and CYP3A2 protein
expression were analysed by means of immunoblotting. Representative images for three independent experiments are shown. (B) After 4 and 7 days of
culture PROD (CYP2B1)-dependent activities were measured. Data are expressed as percentage of the values found for freshly isolated primary rat
hepatocytes, i.e. 7.7 ± 3.1 pmol/min/mg microsomal protein. Values represent mean ± SD (nP 3). (*p < 0.05 compared to control values, paired
Student’s t-test).
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other hand, in EGF-stimulated primary rat hepatocytes,
both combined and single exposure to 5-Aza-dC and 4-
Me2N-BAVAH resulted in dose-dependent inhibition of
the DNA replication and improvement of the hepatic
functionality/phenotype, as evidenced by enhanced
ALB secretion and elevated CYP1A1 protein expression
[73]. Yet, upon combined application, lower concentra-
tions of the respective epigenetic modiﬁers are needed
when compared to single treatment in order to observe
the same –or even a more pronounced– eﬀect, pointing
to a synergetic or even synergistic behaviour of DNMTi
and HDACi with respect to important liver-speciﬁc pro-
cesses [73]. Moreover, the interplay between HDACi/
DNMTi and the expression of hepatic genes emphasizes
a plausible involvement of chromatin remodelling
agents in the acquisition/maintenance of a diﬀerentiated
hepatic phenotype in healthy hepatocytes.
3.3. Epigenetic modiﬁers: a key factor to (re)program
stem cells in vitro?
3.3.1. Stem cell signaling cascades
In vivo, stem cells inhabit restricted niches within an
organ or tissue, directing their self-renewal, diﬀerentia-
tion and cell fate [141–143]. In particular, adult tissue
is renewed through asymmetric division of stem/progen-
itor cells, thereby forming one cell that remains a stem
cell and another cell that diﬀerentiates into a mature cell
type with specialised functions [141–143]. Batteries of
developmental regulatory signaling molecules and tran-
scription factors, including Wnts, ﬁbroblast growth fac-
tors, Notch, sonic hedhodge, etc. may play a role
[85,142,144]. More speciﬁcally, the coordinated signal-
ing between stem cells, non-stem niche cells, the scaﬀold,and integration of stem cell-autonomous characteristics-
including a dynamic interplay between transcription,
epigenetic control and posttranscriptional regulators
represent an interactive system, organized to facilitate
cell-fate decisions in a spatio-temporal manner
[85,142,144]. Identiﬁcation of these in vivo signaling pat-
terns is crucial for eliciting distinct responses from cul-
tured stem cells and directing lineage-speciﬁc cell
growth and diﬀerentiation in vitro. Lately, evidence is
growing that particularly chromatin remodelling or
alteration of epigenetic marks, including histone acetyla-
tion/methylation and DNA methylation are part of the
core machinery required for nuclear reprogramming and
cell-fate conversion [9,12–15,145,146].
3.3.2. The epigenetic control of stem cell diﬀerentiation
Pluripotent ES and more lineage-restricted adult
stem/progenitor cells diﬀer in their global gene
expression status. Stemness genes, active in pluripotent
embryonic stem cells are gradually silenced, whilst line-
age-speciﬁc genes are switched on upon progression of
development [12,14,15,146]. This discrepancy in gene
expression proﬁling might be ascribed to alterations in
the nuclear and chromatin architecture, resulting in
selective accessibility of transcription factors towards
speciﬁc DNA-binding sites. Each stage of lineage-direc-
ted development is thus featured by a dynamic interplay
between unique repertoires of (lineage-speciﬁc) tran-
scription factors and epigenetic regulators. This epige-
netic code forms the base of the stem cell identity and
determines its responsiveness to extrinsic signals at suc-
cessive developmental stages [9,82,85,114]. Alterna-
tively, extracellular growth factors might directly aﬀect
the chromatin status as well and as such facilitate or
impede the diﬀerentiation competence of stem/progenitor
198 S. Snykers et al. / Journal of Hepatology 51 (2009) 187–211cells [147]. Hence, the hypothesis was concocted that cell
fate might be reprogrammed by altering the epigenetic
code/marks.
In this regard, a recent breakthrough was achieved by
Takahashi and Yamanaka, who successfully repro-
grammed mouse embryonic/adult ﬁbroblasts to ES-like
stem cells, referred to as induced pluripotent cells (iPS),
via viral mediated transduction of Oct4, Sox2, c-Myc
and Klf4 [148]. These four transcription factors act as
core regulators of the transcriptional circuitry to main-
tain pluripotency in ES. The theory exists that their
ectopic expression in lineage-committed somatic cells
induces alterations in the histone code and DNA meth-
ylation status of stemness genes such as Oct4, Sox2 and
Nanog [146,148]. Although the underlying mechanism
remains elusive, latter realization emphasizes the tight
epigenetic control of transcriptional machinery regulat-
ing pluripotency and lineage-speciﬁc diﬀerentiation.
More speciﬁcally, on/oﬀ switch of cell fate reprogram-
mation and transcription of lineage-speciﬁc genes may
be poised by dynamic open/closed conﬁguration of his-
tone and nuclear architecture at speciﬁc binding sites for
transcription factors.
Since HDACi and/or DNMTi upregulate the transac-
tivation potential of liver-enriched transcription factors
in a plethora of hepatoma cells and primary hepatocytes
[cf. Table 1], being key regulators of liver embryogenesis
and liver-speciﬁc gene expression in particular, addition
of HDACi and/or DNMTi to stem/progenitor cells,
preferentially co-conditioned with hepatogenic growth
factors and cytokines, is thought to comprise a potential
strategy for driving diﬀerentiation programs and more
speciﬁcally for directing hepatic diﬀerentiation of stem/
progenitor cells. An overview of currently applied epige-
netics-based strategies for in vitro hepatic diﬀerentiation
of ES and MSC is given in Table 2.
3.3.3. Pluripotent embryonic stem cells and multipotent
mesenchymal stem/progenitor cells as source of
hepatocytes
3.3.3.1. Pluripotent embryonic stem cells. ES harbour a
unique pluripotent versatility compared with fetal and
adult multi/bipotent stem/progenitor cell populations.
They posses the unrestricted capacity to form cell types
of the three germ layers, including neuroectodermal
cells, cardiomyocytes and hepatocytes. Yet, spontane-
ous ES diﬀerentiation is encountered by lack of organi-
zation and inherent heterogeneity [149–151].
Introduction of chromatin remodelling agents, biologi-
cally-derived signals such as puriﬁed growth factors, or
other lineage-selective agents, though, could enrich for
speciﬁc cell populations [150]. For example, exposure
to 5 mM sodium butyrate enriches ES cultures for
10–15% to pure hepatic cells [152]. Priming with alter-
nating concentrations of sodium butyrate (0.5–1 mM)
in the presence of Activin A even results in 10–70%enrichment [153]. Basically, combined application of
epigenetic modiﬁcation and stepwise exposure to cyto-
kine stimuli considerably contribute to homogeneity of
the end-population and acquisition of hepatic function-
ality [153].
3.3.3.2. Multipotent mesenchymal stem cells. In recent
years, evidence has been provided that MSC(-like) cells
from various sources (bone marrow/adipose tissue/pla-
centa/umbilical cord) could occasionally overcome line-
age borders and diﬀerentiate into endodermal
(hepatocytes) and ectodermal (neural cells) cell types
upon coordinated in vitro stimulation [154–160]. New
insights into the underlying mechanisms indicate that
next to lineage-speciﬁc cytokines/growth factors (their
concentrations, mode of presentation, and order of appli-
cation) [144], alterations of the epigenetic traits and chro-
matin code of speciﬁc gene regulatory regions are
essential for bypassing cell fate determinism and repro-
gramming cell fate [9,13,15,145,146]. In this context, we
found as ﬁrst that addition of 1 lM TSA to cultured
human bone marrow MSC, pre-treated for 6 days with
hepatogenic-stimulating agents, triggers their ‘trans’dif-
ferentiation into cells with similar phenotypic and func-
tional characteristics as primary hepatocytes [154]. In
line with our results, Seo et al. showed enhanced hepatic
diﬀerentiation upon addition of 0.1% dimethylsulfoxide
to human adipose tissue-derived stem cells (ADSC), pres-
timulated for 10 days with a mixture of hepatogenic cyto-
kines [161]. Likewise, neuroectodermal and
cardiomyocyte direction could be accomplished via co-
exposure to HDACi along with neural stimulating agents
[162] and shear stress [163,164], respectively. Recently
also DNMTi, either alone or in combination with
HDACi, were introduced to alter cell fate [155,165–
167]. Basically, DNMTi function as preconditioning
agents prior to hepatic diﬀerentiation [155,167,168],
whereasHDACi act as stimulants during or post-diﬀeren-
tiation [154,156,161,169]. In general, chromatin remodel-
ling seems thus a potential innovative strategy to
overcome cell fate determinism, cross lineage borders
and favour lineage-speciﬁc diﬀerentiation.We expect that
this ﬁeld will emerge in the upcoming years.
Next to successful diﬀerentiations, also failures have
been reported. For example, 1 mM valproic acid
(VPA), 100 nM TSA and 1 lM sodium butyrate failed
to promote oligodendrocyte or astrocyte diﬀerentiation
in rat neural progenitors under respective stimulating
conditions [162], whilst they could trigger diﬀerentiation
into neural cells in a neural stimulating microenviron-
ment [162]. In addition, Jori and group reported that
2 mM VPA, but not 50 nM TSA, could stimulate neural
transition of MSC [170]. On the other hand, we found
that functional hepatic diﬀerentiation of bone marrow
MSC was especially successful upon exposure of 1 lM
TSA to 6 days preconditioned cells.
Table 2
Detailed epigenetics-based strategies for in vitro diﬀerentiation of ES and MSC-like cells into hepatic cells.
Origin Hepatic diﬀerentiation conditions Hepatic features Refs.
Cell density Cell–matrix/
cell–cell
interaction
Serum Growth factors-cytokines
nonepigenetic
additives
Diﬀerentiation-
inducing agents
RNA +
protein level
Functionality
level
EMBRYONIC STEM CELLS
Hepatic progenitor cells
NS Gelatin 15% FBS (3)D11–17/23: 10 ng/ml
HGF until conﬂuent
(1)D0–4: 0.8% DMSO AFP, a1AT, CK18/19 [182]
(2)D4–10:
2.5 mM SB
GGT, HNF3 b,
DPPIV
mES(D3) Hepatocytes
NS Collagen
type I
10% FBS 4)D17/23–23/29:
insulin, dex
nicotinamide
ALB, G6P", TAT" Glycogen storage
20 ng/ml EGF
ALB secretion
10 ng/ml HGF
(5)from D23/29:
10 ng/ml OSM, dex
hES NS PAU-coating,
nonwoven
PTFE
NS D0–3:100 ng/ml
bFGF
D3–11:
1% DMSO
ALB Lidocaine [173]
D3–11:100 ng/ml
HGF
metabolism
D11–14:dex
ALB and urea
production
hEBs Matrigel 20%FBS 5 mM SB : AFP Glycogen storage [152]
+: ALB, a1AT,
CK8/18
Inducible
CYP450 activity
mES (D3) 1  104 cells/cm2 D0–10:Gelatin
collagen type I
polystyrene
D0–10: 20%
FBS
D0–4:
1% DMSO
+: ALB, K18,
DPPIV ADH,
CYP3A13,
CYP27A1
Glycolysis
D4–10:
2.5 mM SB
Glycogen storage
[183]Urea production
CYP activity
1  104 cells/cm2 D0–10: gelatin
from D11: 5%
polyacrylamide
D0–10:20%
FBS from
D11:/
D0–4:
1% DMSO
Glycogen storage [184]
D11: subculture
at 15  103 cells/cm2
D4-10:
2.5 mM SB
"urea production
From D11:/
"ALB secretion
mES (D3) Phase I
Pre-diﬀerentiation
= no conﬂuence
Gelatin 15%FBS (3) from D10 until
conﬂuence: 10 ng/ml HGF
(1)D0–4:
0.8% DMSO
+: CK19, ALB,
a1AT HNF3b
[182]
(2)D4–10:
2.5 mM SB
-: SSEA1, AFP
Phase II Collagen type I 10%FBS (4) Upon subculture: D0–6:
insulin, dex nicotinamide,
+: AFP, ALB,
CK18, a1AT
HNF3b, HNF4,
TAT
Glycogen storage
Diﬀerentiation
upon conﬂuence
and subculture
20 ng/ml EGF
-: CK19
ALB secretion
10 ng/ml HGF
(5) From D6–12/18:
(5) From D6–12/18: 10 ng/
ml OSM, dex
hES Diﬀerentiation
onset
pon 50–70%
conﬂuence
D3/5:1/2 split
Matrigel D0–3/5:/
D3/5–
D10/12:SR
from
D10/12:
8.3% FBS
D0–3/5: 100 ng/ml activin
A
From D10/12:insulin,
hydrocortisone, 10 ng/ml
HGF, 20 ng/ml OSM
D0-D1/2:1 mM SB D0–3/5: CXCR4,
HNF3b, Sox17
Glycogen storage
ALB/ﬁbrinogen/
ﬁbronectin/A2M
secretion inducible
CYP activity
[153]
D1/2–3/5: 0.5 mM SB
D3/5–D10/12:
HNF4a", HNF1",
TTR"
D3/5–D10/12: 1% DMSO
AFP
From D10/12:ALB,
ApoF, CAR, TO,
TAT", CYP3A4/7,
CYP2C9/19
mES Monkey ES mES:109 cells/
cm3 lumen V
monkey ES:
4103 cells/cm3
lumen V
Organoid
culture
in hollow
ﬁbers
20% FBS D9: 1 mM SB +: CPS" ALB secretion
ammonia removal
[174]
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Table 2 (continued)
Origin Hepatic diﬀerentiation conditions Hepatic features Refs.
Cell density Cell–matrix/
cell–cell
interaction
Serum Growth factors-cytokines
nonepigenetic
additives
Diﬀerentiation-
inducing agents
RNA +
protein level
Functionality
level
MESENCHYMAL(-LIKE) STEM/PROGENITOR CELLS
BM (tibias + femora,
C57/BL6 mice)
1  104MSC/cm2
+5.2  104
liver cells/cm2
Coculture with
nonparenchymal
liver cells
on collagen
>coculture:
20% FBS
12 h before coculture: dex 12 h before
coculture:: 5 mM
5-AzaC
ALB, CK18/8/19,
TAT
[156]
Upon coculture:
5% liver failure
patients
sera
Upon coculture:
nicotinamide, insulin, dex,
50 ng/ml HGF, 20 ng/ml
OSM
Upon coculture:
1% DMSO
ADSC (abdominoplasty,
19–55 years human
adults; P3–5)
2.5–3 
104 cells/cm2
FN / 10 ng/ml HGF From D10 on:
supplement of
0.1% DMSO
AFP, ALB LDL uptake urea
production
[161]
10 ng/ml OSM, ITS
10 ng/ml EGF, dex
BM (iliac crest,
human adults)
100–200cells/
cm2
NS 2% FCS D1:40 ng/ml HGF, 20 ng/
ml EGF
D0:preincubation
with 20 km 5-AzaC
Cx32, HepPar1,
CYP3A4, CPS CK18,
ALB, PEPCK
Glycogen storage
Urea secretion
[185]
ADSC (subcutaneous/
peritoneal, female
donor)
BM (iliac crest and
femora, human)
Diﬀerentiation
onset upon
100% conﬂuence
Cx32, CYP3A4,
CPS CK18, ALB,
PEPCK, DPPIV
Glycogen storage
Urea secretion
[168]
BM (healthy
human; P4–5)
22  103MSC/cm2
diﬀerentiation onset
upon 100%
conﬂuence
Collagen
type I
Prediﬀerentiation:
2% FBS
D0-2: 10 ng/ml FGF4 From D6 on:
supplement of
1 lM TSA
ALB", CK18",
HNF1a", MRP2"
C/EBPa"
ALB secretion",
inducible
CYP activity
Urea secretion
[154]
D3–5: 20 ng/ml HGF from
D6 on:ITS, dex 20 ng/ml
HGF
ADSC (peritonial,
Fischer 344 rats)
200–300 cells/cm2
Diﬀerention onset:
upon 95% conﬂuence:
FN (2)D1: hepatocyte growth
medium
D0: preincubation
with 20 lM
5-AzaC
AFP, ALB, CK18/19,
CYP1A1, HepPar1,
Cx32, DPPIV, PCK1
Glycogen storage [155]
Urea production
UCB (hTERT
retroviral infected)
2.1  103 cells/cm2 NS D1–22:
10% FBS
D1–22: 10 ng/ml FGF2 D0: preincubation
with 1 lM5-AzaC
ALB, C/EBPa/b",
CYP1A1/2,
PEPCK", wnt;
Glycogen storage [167]
20 ng/ml HGF Urea secretion
20 ng/ml OSM
BM (tibias +
femora, SD rats)
22  103MSC/cm2
diﬀerentiation onset
upon 100% conﬂuence
Collagen
type I
Prediﬀerentiation:
2% FBS
D0–2: 10 ng/ml FGF4 From D6 on:
supplement of
1 lM TSA
AFP", ALB",
CK18", HNF1a",
HNF3b
ALB secretion" [169]
D3–5: 20 ng/ml HGF from
D6 on:ITS, dex 20 ng/ml
HGF
Abbreviations: a1AT, alpha1-antitrypsin; ADH, alcohol dehydrogenase; ADSC, adipose tissue-derived stem cells; AFP, alpha-fetoprotein; ALB, albumin; A2M, a2macroglobulin; ApoF, apoli-
poprotein factor; 5-AzaC, 5-azacitidine; bFGF, basic ﬁbroblast growth factor; BM, bone marrow; CAR, constitutive androstane receptor; C/EBP, CCAAT enhancer binding protein; CK,
cytokeratin; CPS CPS-1, carbamyl phosphate synthetase; Cx, connexin; CYP, cytochrome P450-dependent monooxygenases; dex, dexamethasone; DMSO, dimethylsulfoxide; DPPIV, dipeptidyl-
peptidase IV; EGF, epidermal growth factor; ES, embryonic stem cells; FBS, fetal bovine serum; FCS, fetal calf serum; FGF, ﬁbroblast growth factor; FN, ﬁbronectin; GGT, c-glutamyltransferase;
G6P, glucose-6-phosphatase; h, human; HepPar1, hepatocyte paraﬃn 1; HGF, hepatocyte growth factor; HNF, hepatocyte nuclear factor; ITS, insulin-transferrin-selenious acid; LDL, low density
lipoprotein; m, mouse/murine; MRP, multidrug resistance protein; MSC, mesenchymal stem cells; NS, not speciﬁed; OSM, oncostatin M; P, passage; PAU, poly-amino-urethane; PEPCK,
phosphoenol-pyruvate carboxykinase; PTFE, polytetraﬂuoroethylene; SB, sodium byturate; SD, Sprague–Dawley; Sox17, Sry-related HMG box transcription factor; SR, serum replacement; SSEA,
stage-speciﬁc embryonic antigen; TAT, tyrosine amino-transferase; TERT, telomerase reverse transcriptase; TO, tryptophan-2,3-dioxygenase; TSA, trichostatin A; TTR, transthyretin; UCB,
umbilical cord blood; 1.,2.,3; indicate order of serial steps.
;, downregulation; ", upregulation; , negative; +, positive.
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(i) the microenvironment (cell–cell contact, cell densi-
ties), (ii) the appropriate type of epigenetic modiﬁer
and (iii) optimal ﬁne-tuning of its dose and timing –
onset and duration – of exposure [154,161,169,171].
The suitability of HDACi and/or DNMTi to promote
hepatic (trans)diﬀerentiation requires a delicate balance
between (i) proliferation and diﬀerentiation, (ii) biologi-
cal activity, pharmacokinetic properties and toxicologi-
cal characteristics, and ﬁnally (iii) apoptosis and cell
survival. At least in some cases, failure of lineage-spe-
ciﬁc diﬀerentiation could be ascribed to inaccurate tim-
ing of exposure and dosage of chromatin modulating
agents. Basically, although not generally [153], pre-stim-
ulation of the cells towards the intended selected direc-tion prior to introduction of HDACi, may comprise a
key determinant to cross lineage boundaries and achieve
promoted transdiﬀerentiation into a speciﬁc lineage by
means of HDAC inhibition [154,161,164,169,172–174].
An up-to-date overview of both successful and failed
epigenetics-induced cellular (re)programmations of pro-
genitor cells is given in Table 3.
3.3.4. Stem-cell derived hepatocytes or hepatocyte-like
cells?
The diﬀerentiation of embryonic/fetal hepatoblasts
into adult hepatocytes in vivo basically implies consecu-
tive expression of early (HNF-3b, AFP, transthyretin),
midlate (HNF-1a, HNF-4a, ALB, cytokeratin 18) and
late (tryptophan-2,3-dioxygenase, tyrosine amino-trans-
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142,144,175,176]. Most metabolic and detoxifying
enzymes only become functional during the terminal
step of liver organogenesis, i.e. peri/postnatal. There-
fore, functional assays for enzymes, related to speciﬁc
functions of the adult liver [80,177], must be carried
out in order to state the mature status of resultant stem
cell-derived hepatocyte-like cells. At present, functional
analysis is particularly focused on ALB-secretion, urea
metabolism and glycogen uptake. Little attention has
been paid to other metabolic functions, including
CYP450-dependent enzymatic activity and responsive-
ness to prototype inducers such as phenobarbital
(human: CYP2B6, CYP3A4, rat CYP2B1/2), rifampicin
(CYP3A4) and 3-methylcholantrene (human and rat
CYP1A1/2). Bearing in mind that inducible CYP-
dependent activity is considered to be a key determinant
of the functional hepatic phenotype [80,178], character-
ization should preferably comprise the above mentioned
metabolic functionality assays. Alternatively, metabolic
proﬁling using well-known molecules (e.g. paracetamol)
might shed light on their potency as in vitro models for
preclinical toxicological screening of drug candidates.
Recently, Hay and colleagues, in fact succeeded to pro-
duce a nearly (71%) pure population of functional,
metabolism competent hepatocytes out of human ES
via ﬁne-tuned preconditioning with HDACi and growth
factor stimuli [153]. The resultant cells display active and
inducible CYP isozymes, capable of converting various
substrates, e.g. midazolam, bufuralol, phenacetin, tolbu-
tamide and rifampicine, to their respective metabolites,
thereby supporting their potential use as preclinical
in vitro systems for toxicity screening of drugs [153].
The ultimate demonstration of hepatic functionality
is no doubt in vivo transplantation of ex vivo generated
hepatic cells in (immunodeﬁcient) animal models suﬀer-
ing from liver injury. Sgodda and coworkers recently
conﬁrmed the functional integration of hepatic cells
derived from MSC, that were primed with 5-AzaC
prior to combined exposure to hepatocyte growth fac-
tor and EGF [155]. Despite seemingly irrefutable evi-
dence that stem/progenitor cells could contribute to
liver reconstitution, caution should be taken with pro-
duction of false positives due to application of inaccu-
rate labelling techniques [179]. Also, one should keep
in mind that, apart from generating fully functional
stem-cell derived hepatocytes, other mechanisms
including the bystander eﬀect, fusion, partial transdif-
ferentiation and horizontal gene transfer [180,181]
might be responsible.4. Conclusion
During preclinical drug development, early screen-
ing of promising drug candidates with respect to theirmetabolism, pharmacokinetics and potential (toxic)
interactions is encouraged to diminish the number of
failures at later stages. In vitro techniques, including
hepatocyte-based in vitro models, are currently being
applied. Hepatocytes in culture, however, enter the cell
cycle and irreversibly dediﬀerentiate. Their limited via-
bility and major loss of xenobiotic biotransformation
capacity strongly limit their applicability. Understand-
ing how to control diﬀerentiation and proliferation of
these primary cells is a key-challenge. Next to target-
ing the diﬀerentiated status of adult primary hepato-
cytes, stem/progenitor cell technology has been
proposed as an alternative to produce functional
hepatocytes. Until recently the mechanisms governing
lineage-directed and terminal diﬀerentiation in these
stem/progenitor cells and adult primay cells, respec-
tively, largely have remained unknown. In this review,
we provide a better understanding of the intracellular
regulation of directed and established liver-speciﬁc
gene transcription.
In vivo, a constellation of intra- and extra-cellular sig-
naling pathways is known to govern the balance of
growth and diﬀerentiation in all cells. Stem cells, their
diﬀerentiated progeny-including adult hepatocytes, and
elements of their microenvironment make up a struc-
tural, (epi)genetic controlled machinery that coordinates
normal homeostatic functioning of these cells
[3,5,85,113,114,142–144]. By extensively reviewing the
literature, we realised that next to the reconstruction
of extracellular communication pathways in vivo (line-
age-speciﬁc factors, including growth factors, cytokines,
hormones, glucocorticoids, cell–cell and cell–matrix
interactions), interference at the intracellular level via
chromatin remodelling agents might involve a strategy
to control lineage-speciﬁc gene expression, and conse-
quently (i) the multilineage diﬀerentiation potency of
stem cells and (ii) the acquisition of a diﬀerentiated
genotype in adult cells [9,12–15,82,85,114,49,52,128,
129,135,137,145,146]. Gene expression is in fact largely
regulated by epigenetic modiﬁcations of DNA and chro-
matin on genomic regulatory and coding regions. In
general, acetylation of core histones is associated with
transcriptional activation, whereas DNA methylation
is associated with gene silencing [17,20]. However, as
reviewed in Tables 1–3, diﬀerential eﬀects are observed
depending on the factors studied e.g. the origin of the
cells, the property evaluated, the type of epigenetic mod-
iﬁer used and the exposure time. Nevertheless, from the
presented data it appears that in several stem cells-
derived and primary hepatic-based models both HDACi
and DNMTi are potent modulators of liver-speciﬁc
functions and cellular contacts, and as such could signif-
icantly contribute to the acquisition and maintenance of
the hepatocyte-speciﬁc geno/phenotype in culture.
Up to now, HDACi and DNMTi are mostly applied
separately, though, their combined exposure is advanta-
Table 3
Accomplished and failed HDAC and DNMT inhibitor-induced in vitro and in vivo diﬀerentiation of stem cells into various cell types.
Epigenetic modiﬁer Culture conditions Stem cell type Intended cell type Observed features Reference
(A) Successful (‘trans’)diﬀerentiation
HDAC inhibitor
TSA* 1 lM TSA Human bone
marrow MSC
Hepatocyte-like cells Increased Alb,
CK18, HNF1a,
MRP2, C/EBPa
expression and Alb
secretion
[154]
Exposure from day 6 of
diﬀerentiation onwards
Hepatic stimulating medium
TSA* 1 lM TSA Rat MPC Hepatocyte-like cells Increased AFP,
HNF, Alb, CK18,
C/EBPa, CYPs
expression and Alb
secretion
[169]
Exposure from day 6 of
diﬀerentiation onwards
Hepatic stimulating medium
DMSO* 0.1% DMSO Human ADSC Hepatocyte-like cells Alb and AFP
expression, urea
production
[161]
Exposure from D10 of
diﬀerentiation
Hepatic stimulating medium
DMSO* (1) 1% DMSO Human ES Hepatocyte-like cells Alb expression,
lidocaine
metabolism, Alb and
urea production
[173]
Exposure from D3–11 of
diﬀerentiation
Hepatic stimulating medium
DMSO + sodium butyrate* (1) 1% DMSO Murine ES (D3) Hepatocyte-like cells Alb, CK18, DPPIV,
ADH, CYP
expression,
[183,184]
Exposure from D0–4 of
diﬀerentiation
(2) 2.5 mM sodium butyrate
Exposure from D4–10 of
diﬀerentiation
DMSO + sodium butyrate* (1) 0.8% DMSO
Exposure from D0–4 of
diﬀerentiation
(2) 2.5 mM sodium butyrate
Exposure from D4–10 of
diﬀerentiation
From D11: hepatic stimulating
medium
Murine ES (D3) Hepatocyte-like cells AFP, ALB, a1AT,
CK18, CK19, GGT,
HNF3b, G6P, TAT
and DPPIV
expression, glycogen
storage, ALB
secretion
[182]
Sodium butyrate* 1 mM Sodium butyrate urine and monkey
ES
Hepatocyte-like cells Alb expression, urea
and Alb secretion
[174]
Exposure from D9 of culture
Unspeciﬁed diﬀerentiation medium
Sodium butyrate + DMSO* (1) 1 mM sodium butyrate Human ES Hepatocyte-like cells Expression of CYPs,
HNF3b, HNF4a,
HNF1a,b, TTR,
AFP, Alb, ApoF,
CAR, TO, TAT,
glycogen storage,
Alb/ﬁbrinogen/
ﬁbronectin/A2M
secretion, CYP
activity
[153]
Exposure upon 50–70% conﬂuence
for 24–48 h
(2) 0.5 mM sodium butyrate
Exposure from D1-2 of
diﬀerentiation for 48-72 h
(3) 1% DMSO
Exposure from D3 to D5 of
diﬀerentiation upon subculture for
7days
Hepatic stimulating medium
TSA* + shear stress 10 ng/ml TSA ES (129/Ola derived) Cardiomyocytes Increased acetylated
GATA-4, b-MHC,
Nkx2.5 and ANF
expression
[164]
Shear stress: concentration not
speciﬁed
24 h exposure after 7 days of
diﬀerentiation
Unspeciﬁed diﬀerentiation medium
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Table 3 (continued)
Epigenetic modiﬁer Culture conditions Stem cell type Intended cell type Observed features Reference
TSA* + shear stress 32 nM TSA Murine ES (D3) Cardiovascular cells Increased VEGFR2,
PECAM, SMA,
SM-2 C, a-SA, etc.
expression
[163]
Exposure from onset of
diﬀerentiation
Shear stress: concentration not
speciﬁed
1–24 h exposure to TSA pre-
incubated cells
Unspeciﬁed diﬀerentiation medium
TSA* 80 nM TSA Embryos cloned
from cow donor cells
Blastocysts Change in
morphology
[172]
24 h exposure after 7 days of
diﬀerentiation
Non-stimulating medium
TSA* 100 nM TSA Rat neural
progenitors
Neural cells Increased Tuj1 or
MAP2ab expression
[162]
VPA* 0.3–1 mM VPA
Sodium butyrate* 1 lM Sodium butyrate
4 days exposure upon onset of
diﬀerentiation
Neural stimulating medium
VPA + DMSO* 2 mM VPA, 2% DMSO
Exposure from diﬀerentiation
onwards
Neural stimulating medium
Rat bone marrow
MSC
Neurons and
astrocytes
Increased expression
of NSE and NF,
AchE activity
[170]
VPA* 0.5–3 mM VPA
Exposure during ﬁrst 3 days of
diﬀerentiation and ﬁrst 4 days prior
to diﬀerentiation
Human bone
marrow MSC
Osteoblasts Increased osterix,
osteopontin BMP-2
and Runx2
expression
[218]
DNMT inhibitor
5-AzaC*,$ 20 lM 5-AzaC Rat ADSC Hepatocyte-like cells Expression of
DPPIV, Alb,
CYP1A1, HepPar1,
AFP, CK19, PCK1,
CK18
[155]
Exposure for 24 h upon
95%conﬂuence prior to
onset of diﬀerentiation
Upon 24 h: Hepatic stimulating
medium
5-AzaC*,$ 20 lM 5-AzaC
Exposure for 24 h prior to hepatic
stimulation onset of diﬀerentiation
at 100% conﬂuency
Hepatic stimulating medium
Human ADSC
Human bone
marrow MSC
Hepatocyte-like cells Expression of Alb,
CYP3A4, HepPar1,
CK18, Cx32,
PEPCK, CPS
and Cx32, urea
production,
glycogen storage
[168,185]
5-AzaC*,$ 1 lM 5-AzaC Human umbilical
cord blood MSC
Hepatocyte-like cells Expression of Alb,
C/EBPa, CYP1A1/
2, glycogen storage
[167]
Exposure for 24 h prior to hepatic
stimulation
Hepatic stimulating medium
HDAC + DNMT inhibitor
TSA + 5-Aza-dC$ 150 nM TSA + 500 nM 5-Aza-dC Murine neurosperes Haematopoietic cells Expression of CD45,
CD3, CD19, MAC1,
CD4, CD8
[166]
2days exposure prior to
transplantation
Neural stem cell stimulating
medium
TSA + 5-Aza-dC$ 5 ng/ml TSA + 500 nM 5-Aza-dC Human CD34+ HSC CD34+/CD90+
HPC
Marrow
repopulating
capability, self-
renewing potential
[165]
5-Aza-dC: exposure from 16 to 48 h
cultivation in medium promoting
exit of G0/G1 phase
TSA: exposure from 48 h
cultivation in medium promoting
terminal diﬀerentiation
(continued on next page)
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Table 3 (continued)
Epigenetic modiﬁer Culture conditions Stem cell type Intended cell type Observed features Reference
DMSO + AzaC* 1% DMSO + 5 mM 5-AzaC Murine bone
marrow MSC
Hepatocyte-like cells Expression of Alb,
TAT, CK18/8,
CK19
[156]
AzaC: exposure for 12 h before
coculture
DMSO: exposure throughout
culture time
Hepatic stimulating medium
Coculture with nonparenchymal
liver cells
(B) Failure of (‘trans’)diﬀerentiation
HDAC inhibitor
TSA + VPA + DMSO* 50 nM TSA, 2 mM VPA, 2%
DMSO
Rat bone marrow
MSC
Neurons and
astrocytes
Decreased
expression of NSE
and NF, Decreased
AchE activity
[170]
Exposure upon D1 of
diﬀerentiation onwards
Neural stimulating medium
Butyrate* 2 mM Butyrate Mononuclear cells
from murine/human
peripheral blood/
bone marrow/spleen
Endothelial cells Failure of HoxA9,
VEGFR2 expression
[219]
TSA* 1–2.5 lM TSA
MS-275* 3–10 lM MS-275
Exposure upon onset of
diﬀerentiation
Endothelial stimulating medium
TSA* 5 or 10 nM TSA
Exposure upon onset of
diﬀerentiation
Unspeciﬁed diﬀerentiation medium
Murine ES Embryoid bodies Steady alkaline
phosphatase activity
[220]
VPA* 0.3–1 mM VPA Rat neural
progenitors
Astrocytes,
oligodendrocytes
Failure of Rip and
GFAP expression
[162]
TSA* 100 nM TSA
Sodium butyrate* 1 lM Sodium butyrate
Exposure for 4 days upon onset of
diﬀerentiation
Oligodendrocyte and astrocyte
stimulating medium
VPA* 0.5–2 mM VPA Mouse 3T3-L1
preadipocytes
Adipocytes Reduced PPARc,
SREBP1a, C/EBPa
expression
[221]
TSA* 3 nM TSA
Exposure after 2 days of conﬂuence
Diﬀerentiation inducing medium
Primary human
preadipocytes
(C) Time-speciﬁed related failure/ accomplishment of (‘trans’)diﬀerentiation
HDAC inhibitor
VPA$ 300 mg/kg VPA
Injection: every 12 h, for 4 times
- In postnatal weeks 1–2
- From postnatal week 3 onwards
Pups neural
progenitor cells
Oligodendrocytes
- Suppression of
myelination
- No suppression
of myelination
[171]
TSA* 5–400 nM TSA Mouse myoblasts Myotubes [222]
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Table 3 (continued)
Epigenetic modiﬁer Culture conditions Stem cell type Intended cell type Observed features Reference
Sodium butyrate* 0.1–10 mM Sodium butyrate
VPA* 0.1–10 mM VPA
Diﬀerentiation inducing medium
- Exposure from onset of
diﬀerentiation
- Prevention of
muscle
diﬀerentiation
- Exposure after onset of
diﬀerentiation
- Progression of
terminal muscle
diﬀerentiation and
prevention of
reorganisation of
constitutive
heterochromatin
TSA* 0.1, 1 and 10 ng/ml TSA Rat oligo-
dendrocyte
progenitors
oligodendrocytes [223]
Pre-treated neuroectodermal
stimulating medium
- Exposure up to to 12–24 h upon
mitogen removal
- Steady state
expression of A2B5,
no oligodendrocyte
maturation
- Exposure after 24 h upon mitogen
removal
- Failure of GAIC
and PLP expression,
oligodendrocyte
maturation (20)
Abbreviations: a1AT, alpha1-antitrypsin; AChE, acetylcholinesterase; ADH, alcohol dehydrogenase; ADSC, adipose tissue-derived stromal cells;
AFP, alpha-fetoprotein; ALB, albumin; A2M, alpha-2 macroglobulin; ANF, atrial natriuretic factor; ApoF, apolipoprotein; a-SA, alpha-sarcomeric
actin; AzaC, 5-azacytidine; 5-Aza-dC, decitabine 5-Aza-20deoxycytidine; b-MHC, beta-myosin heavy chain; BMP-2, bone morphogenic protein;
CAR, constitutive androstane receptor; CD, cluster of diﬀerentiation; C/EBP, CCAAT enhancer binding protein; CK, cytokeratin; CPS, carbamyl
phosphate synthetase; Cx, connexin; CYP, cytochrome P450; DMSO, dimethylsulfoxide; DPPIV, dipeptidyl peptidase IV; DNMT inhibitor, DNA
methyltransferase inhibitor; ES, embryonic stem cells; GAlC, galactocerebroside; GFAP, glial ﬁbrillary acidic protein; HDAC inhibitor, histone
deacetylase inhibitor; HNF, hepatocyte-nuclear factor; HSC, haematopoietic stem cells; Hox, homeobox; LDL, low density lipoprotein; MAC1,
macrophage antigen-1; MAP, microtubule-associated protein; MPC, mesenchymal progenitor cells; MRP, multidrug resistance protein; MSC,
mesenchymal stem cells; NF, neuroﬁlament; Nkx2.5, NK2 transcription factor related locus 5; NSE, neuron speciﬁc enolase; PCK1, phospho-
enolpyruvate carboxykinase; PeB, peripheral blood; PECAM, platelet and endothelial cell adhesion molecule; PEPCK, phosphoenol-pyruvate
carboxykinase; PLP, proteolipid protein; PPARc, peroxisome proliferator-activated receptor gamma; Rip, oligodendrocyte marker; Runx2, tran-
scription factor vertebrate homologue of the Drosophila runt gene 2; SMA, smooth muscle actin; SREBP, sterol regulatory element binding protein;
SS, shear stress; TAT, tyrosine aminotransferase; TO, tryptophan dioxygenase; TSA, trichostatin A; TTR, transthyretin; VEGFR2, vascular
endothelial growth factor receptor type 2; VPA, valproic acid.
$ in vivo.
* in vitro.
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lowing years. Still, more in depth studies are needed to
unravel the tangled web of epigenetic marks and line-
age-speciﬁc transcription, governing the multipotent sta-
tus of stem cells and the terminal diﬀerentiated geno/
phenotype of adult cell types.Acknowledgements
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